Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Meletios A. Dimopoulos, Fredrik Schjesvold, Vadim Doronin, Olga Vinogradova, Hang Quach, Xavier Leleu, Gonzalez montes Yolanda, Karthik Ramasamy, Alessandra Pompa, Mark-David Levin, Cindy Lee, Ulf-Henrik Mellqvist, Roland Fenk, Hamdi Sati, Alexander Vorog, Richard J. Labotka, Jichang Du, Mohamed Darif, Shaji Kumar
Institutions: Oslo University Hospital, University of Oslo, City Clinical Hospital, Botkin Hospital, The University of Melbourne, St Vincent's Hospital Melbourne, Inserm, Centre Hospitalier Universitaire de Poitiers, Oxford University Hospitals NHS Trust, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Albert Schweitzer Ziekenhuis, Queen Elizabeth Hospital, Düsseldorf University Hospital, Swansea Bay University Health Board, Singleton Hospital, Takeda Oncology (United States), Mayo Clinic
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3166256473